Intel stock extends gains after report of possible U.S. government stake
Investing.com - Guggenheim raised its price target on Compass Therapeutics (NASDAQ:CMPX) to $12.00 from $10.00 while maintaining a Buy rating following the company’s second-quarter 2025 results. The stock has shown remarkable momentum, delivering a 195% return over the past year and 130% year-to-date, according to InvestingPro data.
The biotech company reported positive pipeline updates, including a revised timeline for the final PFS & OS analysis of its COMPANION-002 Phase 2/3 trial of tovecimig in biliary tract cancer, now expected in the first quarter of 2026 instead of the fourth quarter of 2025.
Compass also announced encouraging initial clinical data from its Phase 1 study of CTX-8371, a PD1 x PD-L1 bispecific antibody, showing two confirmed monotherapy responses among 12 treated patients, with some experiencing deep tumor reductions of up to 100% in target lesions. Get deeper insights into Compass Therapeutics’ potential with InvestingPro’s exclusive research report, featuring comprehensive analysis and key metrics.
The company remains on track for fourth-quarter 2025 IND submission of CTX-10726, its PD-1 x VEGF-A bispecific antibody, and presented preclinical data suggesting superiority over competitor Akeso’s ivonescimab.
Guggenheim cited the addition of probability-of-success-adjusted value for CTX-8371 and increased confidence in tovecimig as key factors behind the price target increase.
In other recent news, Compass Therapeutics reported its second-quarter 2025 financial results, revealing a net loss of $19.9 million and earnings per share (EPS) of -$0.14. This EPS result was slightly wider than the anticipated loss of -$0.12, marking a 16.67% negative surprise. Despite this, Raymond (NSE:RYMD) James maintained its Outperform rating for Compass Therapeutics, setting a price target of $9.00. The company ended the quarter with approximately $101 million in cash and equivalents, which management expects will support operations into 2027. These developments reflect ongoing investor interest and analyst confidence in Compass Therapeutics, despite the earnings miss.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.